Cosmo Pharmaceuticals N.V. (0RGI)

Overview

Cosmo Pharmaceuticals N.V., established in 1997 and strategically headquartered in Dublin, Ireland, is a pioneering entity in the healthcare sector, with its focus extensively spread across the development and commercialization of innovative products catering to gastroenterology, dermatology, and healthtech on a global scale. The company harnesses the power of cutting-edge technology, including artificial intelligence, to revolutionize treatments and diagnostics, thereby offering superior healthcare solutions worldwide. Through its dynamic approach towards addressing pivotal health concerns, Cosmo Pharmaceuticals stands as a beacon of progress in the medical field, underpinned by robust partnerships and strategic collaborations with leading healthcare companies and institutions globally.

Products and Services

• GI Genius: This innovative computer-assisted system uses real-time artificial intelligence to detect colorectal lesions, offering a significant advancement in colorectal cancer screening and diagnostics.

• Winlevi: A prescription medicine designed for topical use to treat acne vulgaris, providing a novel approach to managing this common skin condition.

• Lialda/Mezavant/Mesavancol: This once-daily mesalamine tablet is approved to induce remission in patients with active, mild to moderate ulcerative colitis, representing a cornerstone in the management of this inflammatory bowel disease.

• Uceris/Cortiment: An oral tablet formulation delivering budesonide directly to the colon’s lumen, offering targeted therapy for ulcerative colitis with the convenience of oral administration.

• Eleview: A submucosal injectable composition that enables endoscopists to perform faster and less risky excisions of gastrointestinal lesions, enhancing the safety and efficiency of endoscopic procedures.

• Lumeblue: A diagnostic drug used during colonoscopies for the enhanced visualisation of colorectal lesions, contributing to more accurate diagnostics and treatment planning.

• Aemcolo/Relafalk: Approved for treating travelers' diarrhea, this pharmaceutical drug product in tablet form addresses a significant health concern for international travelers, ensuring effective management and relief.

• Byfavo: An intravenous benzodiazepine sedative/anesthetic used in various medical procedures, offering rapid onset and predictable sedation depth for improved patient management and comfort.

In addition to these offerings, Cosmo Pharmaceuticals N.V. is actively engaged in the development of novel therapies and solutions that promise further advancements in medical care. Among these are Breezula, a Phase III androgen receptor inhibitor for scalp treatment targeting hair loss; Rifamycin SV MMX – IBS-D, a Phase III trial formula for treating colonic infections and irritable bowel syndrome with diarrhea; CB-03-10, a Phase I oral androgen receptor antagonist for solid tumors; CB-01-33, under preclinical studies for bile acid diarrhea; and CB-01-35, a Phase II enema solution for distal ulcerative colitis and proctitis, showcasing the company’s commitment to broadening its portfolio and enhancing healthcare outcomes across various conditions.

Cosmo Pharmaceuticals also maintains a strategic network of development, distribution, and licensing agreements with notable entities including Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited, further solidifying its position as a key player in the global healthcare market.